Bovine noroviruses belong to the family Caliciviridae, genus Norovirus. Two genotypes have been described and viruses genetically related to the Jena and Newbury2 strains have been classified into genotypes 1 and 2, respectively. In this study, virus-like particles (VLP) of the previously detected B309 Belgian strain, genetically related to genotype 2 bovine noroviruses, were used to investigate virus-host interactions in vitro. B309 VLP were shown to bind to several bovine cell lines. This binding was not affected by heparinase or chondroitinase treatment but was significantly inhibited by both sodium periodate, a-galactosidase, trypsin and phospholipase C treatment. Cell treatment by neuraminidase also moderately affected this binding. Taken together, these results show that, in addition to a galactosyl residue, sialic acid could also be involved in binding to susceptible cells. In addition, both the cholesterol-dependent pathway and macropinocytosis are used for B309 VLP internalization by Madin-Darby bovine kidney cells. The data increase the knowledge on bovine norovirus cell interactions.
INTRODUCTION
Norovirus (NoV)-like sequences and particles are found in several animal species (Mauroy et al., 2008; Scipioni et al., 2008) including the bovine species (Bridger et al., 1984; Woode & Bridger, 1978) . They are non-enveloped, ssRNA viruses belonging to the genus Norovirus, the family Caliciviridae, in which four other genera (Vesivirus, Lagovirus, Sapovirus and Nebovirus) are also currently officially described (Green, 2007; http://www.ictvonline. org/virusTaxonomy.asp?version=2009) . Animal NoV and human noroviruses (HuNoV), steadily reported as the main viral aetiology in an overwhelming proportion of human gastroenteritis cases and outbreaks, are divided into five genogroups (G) on the basis of phylogenetic analysis. All bovine norovirus (BoNoV) sequences fall into GIII which is further divided into two genotypes. BoNoV genetically related to the reference strains Jena virus (JV) or Newbury2 (NB2) are classified into genotypes 1 and 2, respectively (Liu et al., 1999; Oliver et al., 2007) . To date, the large majority of NoV sequences detected in the bovine species have been genetically related to the NB2 genome and thus, this genotype seems to be the most prevalent worldwide (Han et al., 2004; Ike et al., 2007; Mauroy et al., 2009a, b; Milnes et al., 2007; Park et al., 2007; van Der Poel et al., 2003; Wise et al., 2004) .
The study of NoV has been historically hampered by the lack of an efficient cell culture system (Duizer et al., 2004) , which is still not available for BoNoV. However, virus-like particles (VLP) can be rapidly obtained by different protein expression systems and these VLP have been shown to be morphologically and antigenically similar to the native strain (Han et al., 2005; Jiang et al., 1992) . Viral attachment can be facilitated by cell surface molecules recruiting viral particles into the extracellular compartment and facilitating their presentation to a cell-specific receptor (Smith & Helenius, 2004) . In this way, carbohydrates belonging to glycoaminoglycan chains of the cell surface proteoglycans and glycoproteins are often used by viruses (Vanderplasschen et al., 1993) . During co-evolution with their host, shift in receptor usage and capacity to exploit an alternative entry pathway may enhance the viral adaptation and modify their host range and their pathogenesis (Baranowski et al., 2001) . Several carbohydrate-binding patterns have been described for the family Caliciviridae. Although junctional adhesion molecule 1 was identified as a specific receptor for all feline calicivirus (FCV) strains (Makino et al., 2006; Ossiboff & Parker, 2007) , a2,6-linked sialic acid was shown to play the role of an anchor in the primary binding steps for some FCV strains (Stuart & Brown, 2007) . Rabbit hemorrhagic disease virus (RHDV) mediates haemagglutination, which has been explained by its ability to bind to carbohydrate structures related to the human blood group antigens (HBGA) expressed on human red blood cells (Ruvoën-Clouet et al., 2000) . These HBGA have been recognized for several years as candidate-binding factors for HuNoV, with different binding patterns independent of the genotype classification (Tan & Jiang, 2005) . Recently, Zakhour et al. (2009) identified the a-gal epitope (Gala1,3Galb1,4GlcNAc-R, known as Galili epitope), also related to the HBGA family (Macher & Galili, 2008) , as a terminal residue involved in the binding of a NB2-related BoNoV. However, the concept of multi-receptor usage in the genus Norovirus was reinforced by the report of GII HuNoVLP binding to heparan sulphates by Tamura et al. (2004) and a recent outbreak caused by a GI.3 genetically related HuNoV affecting human regardless of their secretor-, Lewis-or ABO-status (Nordgren et al., 2010) . The use of sialic acid residues was also shown for the binding of some human and murine norovirus (MuNoV), MNV-1 strain Taube et al., 2009 ).
FCV entry pathway was shown to be dependent on clathrin-mediated endocytosis and acidification in endosomes (Stuart & Brown 2006) , whereas MuNoV endocytosis into permissive murine macrophages is mediated by a non-clathrin, non-caveolae, dynamin and cholesteroldependent, pH-independent pathway (Gerondopoulos et al., 2010; Perry et al., 2009; Perry & Wobus, 2010) .
The aim of this study was to elucidate BoNoV-cell interactions during their binding and their internalization. GIII.2 BoNoVLP from the B309 strain (Mauroy et al., 2009a) were used in in vitro studies with different cell lines, in particular those of bovine origin, in order to characterize the cell surface recognition pattern and entry mechanisms.
RESULTS
The structures involved in the binding of GIII.2 BoNoVLP are widely expressed and are related to carbohydrate structures B309 VLP were incubated on monolayers of cell lines of different origins. Binding of B309 VLP was detected by immunofluorescence staining on all the bovine cell lines used in this study: Madin-Darby bovine kidney cells (MDBK), bovine turbinate cells (BT), embryonic bovine tracheal cells (EBTr), Georgia bovine kidney cells (GBK), embryonic bovine lung cells (EBL), Mac T-cells (udder origin), bronchial cells, Bomac cells (macrophagic origin) and jejunocytes. No staining was shown when cells were pretreated with sodium periodate (NaIO 4 ), a strong oxidizing agent opening saccharide rings (data only shown for MDBK cells). The specificity of this binding was controlled by the absence of fluorescence signals on cells incubated with either wild-type baculovirus (Autographa californica multiple nucleocapsids polyhedrovirus, AcMNPV) antigens or heterologous HuNoV Hawaii virus (HV) VLP (Fig. 1a-c) .
Taken together, these results suggest that B309 VLP are able to bind to cells originating from a wide range of tissues and that this primary binding is mediated by structures related to terminal carbohydrate residues.
Cell treatment by a-galactosidase, trypsin and phospholipase C drastically reduces B309 VLP binding, and cell treatment by neuraminidase partially reduces the binding MDBK were treated with different enzymes and then incubated with B309 VLP in experimental conditions decreasing internalization (4 u C and use of sodium azide as cell metabolism inhibitor). Percentages of fluorescent cells and total fluorescence were quantified by flow cytometry. Cell treatment with different concentrations of NaIO 4 confirmed previous results obtained with immunofluorescence staining on cell layers. Mean fluorescence intensity drastically diminished with 50 mM NaIO 4 (note that this last concentration was severely toxic for cells). Among the various enzymes used in this study, binding of B309 VLP was significantly reduced (percentages of fluorescent cells were reduced by up to 70 %) by pre-treatment of MDBK cells with a-galactosidase (0.5 U), trypsin (1 mg) and phospholipase C. Trypsin, chymotrypsin, phospho-Nglycanase and neuraminidase activities were controlled as shown in Supplementary Material (available in JGV Online). Percentages of fluorescent cells and fluorescence intensities were 76 and 81 %, 70 and 79 %, 77 and 79 %, 94 and 82 % lower after treatment with 0.5 U a-galactosidase, 1 mg trypsin, 0.1 U phospholipase C and 0.5 U phospholipase C, respectively. Neuraminidase pre-treatment at 0.5 U partly reduced the binding of B309 VLP by 34 % in both percentage of fluorescent cells and fluorescence intensity analysis (Fig. 2a, c, e) . When cells were treated with both a-galactosidase (0.5 U) and neuraminidase (0.5 U) or both trypsin (1 mg) and phospholipase C (0.5 U), binding was also significantly reduced, with a percentage of fluorescent cells similar to that of negative controls for the second combined treatment (Fig. 2b, d ). Taken together, these results show that a galactosyl residue is closely involved in the binding of the B309 VLP and that it is linked to either membrane glycoproteins or glycosylphosphatidylinositol-anchored proteins. Sialic acid could either be a minor alternative-binding factor or facilitate the attachment to the a-galactose residue. As combined agalactosidase/neuraminidase treatment did not completely reduce the binding, another structure (carbohydraterelated or not) could also be involved.
Heparan or chondroitin sulphates are not implicated in the binding of GIII.2 BoNoVLP B309 VLP binding was not significantly modified after heparinase II or chondroitinase ABC (activities controlled as shown in Supplementary Material) treatment of MDBK cells by flow cytometry analysis (Fig. 3) . Taken together, these results show that the heparan and chondroitin sulphates, widely used by some other viruses, are not alternative carbohydrate structures used in the binding of B309 VLP.
B309 VLP internalization is temperature dependent
B309 VLP were incubated with both MDBK or bovine macrophage cells in experimental conditions allowing their internalization. In this experiment, a fluorescence decrease reflected an internalization of VLP. By comparison in flow cytometry analysis, fluorescence intensity was shown to be about 61 and 34 % lower at 37 u C than at 4 or 21 u C, respectively ( Fig. 4a ) for MDBK cells, where internalization was also confirmed by confocal microscopy (Fig. 4b) . In bovine macrophages, fluorescence intensity was shown to be about 51 % lower at 37 u C than at 4 u C (Fig. 4c ). Taken together, these results show internalization in both cell lines and that the internalization rate of B309 VLP was higher at 37 u C.
Internalization of B309 VLP requires intact actin skeleton, is pH dependent and involves both caveolae/lipid raft-mediated endocytosis and macropinocytosis
The internalization pathway of B309 VLP was then tested in the same flow cytometry experiment. B309 VLP internalization was undertaken at optimal temperature (37 u C) and without the use of sodium azide. Before exposure to BoNoVLP, cells were incubated with different drugs known to be endocytosis inhibitors. The optimum drug concentration to avoid cell toxicity was determined by the MTT test (the effect of the drugs on internalization pathways and the concentrations used on MDBK cells in this study are shown in Table 1 ). Among the drugs used, cytochalasin D (2 mM), chloroquine (600 mM) and amiloride hydrochloride (50 mM) were found to slightly increase the percentage of fluorescent cells, and both cytochalasin D, chloroquine (600 mM) and nystatin (50 mM) increased cell fluorescence intensity after flow cytometry analysis (Fig. 5a ), inducing a reduction in B309 VLP internalization. This result was confirmed in an immunofluorescent staining experiment where internalization was reduced during incubation time in cytochalasinor chloroquine-treated cells (Fig. 5b) . In the second experiment, upon increased concentrations of drugs and chlorpromazine, percentages of fluorescent cells and fluorescence intensity varied with amiloride hydrochloride and nystatin (Fig. 5c ), but not with chlorpromazine (chlorpromazine activity was controlled in CrandellReese feline kidney cells (CrFK) cells, as shown in Supplementary Material). Taken together these results show that the actin skeleton is deeply involved in the internalization of B309 VLP, that drugs interfering with endosomal pH decrease the internalization and that B309 VLP entry is mediated both by the cholesterol-dependent pathway and by macropinocytosis.
DISCUSSION
Genotype 2 BoNoV are widespread enteric viruses throughout the world, for which interactions with the host cell and the role in calf diarrhoea complex are poorly elucidated. Zoonotic transmission is suspected and discussed for these viruses. This study shows that carbohydrate structures, widely expressed on different bovine cells, but also on some other animal cells, are implicated in the binding of genotype 2 BoNoV (B309) VLP. Furthermore, it also shows that carbohydrate residues related to galactose are deeply involved in the binding of B309 VLP. Sialic acid could also be implicated, but in a less important manner and heparan sulphates are not. By studying entry mechanisms, we demonstrated that B309 VLP internalization mainly involves both the cholesterol-dependent pathway and macropinocytosis.
The proximity, in terms of receptors, between HuNoV and animal NoV, in particular BoNoV, is one of the risk factors that need to be studied in order to investigate the zoonotic issue. The zoonotic hypothesis is strengthened by the coexistence of these viruses in areas of high human and animal population density, by their usual faecal-oral route of infection, and by their resistance in the environment. Different molecules, often related to carbohydrate structures, can act as 'hooks' specifically or non-specifically recruiting viral particles into the extracellular compartment. Recently, Zakhour et al. (2009) described the a-gal epitope as a molecular structure implied in the binding of NB2 VLP. The same authors also showed that NB2 VLP do not bind to carbohydrate structures classically described in the binding of HuNoV (H type 1, H type 2, ABO antigens and Lewis antigens). These results and the loss during the evolution of Galili epitope expression by the human species (Macher & Galili, 2008) both suggest an absence of GIII.2 BoNoV cross-species transmission. The results of our flow cytometry study on binding inhibition showed that cell treatment with a-galactosidase drastically reduces the binding of B309 VLP. These results are in agreement with those obtained with VLP of the NB2 strain by Zakhour et al. (2009) and for VLP from another GIII.2-related BoNoV. In our study, B309 VLP-binding capabilities to a wide spectrum of bovine cells was also demonstrated.
These results have shown the wide expression of the structure implicated in the binding and suggest a likely extended pathogenicity if the virus could be disseminated in the organism and if these cells could be permissive. Therefore, for the health and well-being of the calf, GIII.2 BoNoV could be considered to be an enteric pathogen as important as rotaviruses, for which associated viraemia has been recently demonstrated (Crawford et al., 2006) .
Viruses can bind to alternative ligand for example when their primary target is occupied or inaccessible (Cilliers et al., 2005; Harouse et al., 1991; Jin et al., 2010; Khan et al., 2007; Negrete et al., 2006; Yanagi et al., 2009) . Heparan sulphates are ubiquitous carbohydrate chains linked to the core protein of all eukaryotic cells and are often reported to be primary binding structures for several viruses (Villanueva et al., 2005) . They have been shown to efficiently bind GII NoV (Tamura et al., 2004) . In our study, we tested the hypothesis that heparan or chondroitin sulphates could alternatively bind GIII.2 BoNoV. As no observed difference in the binding pattern was shown between non-treated and heparinase-or chondroitinasetreated cells, we conclude that neither heparan nor chondroitin sulphates were involved in the binding of B309 VLP. Sialic acid moieties of gangliosides bind MuNoV during infection of murine macrophages . As sialic acid is a common structure of the membrane of several animal cells and as it has been shown to be involved, even in a moderate way, in the binding of B309 VLP, it could enlarge the host spectrum of GIII.2 BoNoV or provide them with a minor alternative ligand. Alternatively, sialic acid could be involved in one of the sequential steps between binding and internalization of the viral particle or facilitate the binding to the a-galactose residue.
In order to invade cells, viruses use all available endocytic pathways, including clathrin-mediated endocytosis, caveloae/lipid raft, macropinocytosis and novel nonclathrin non-caveolae pathways (Marsh & Helenius, 2006; Sieczkarski & Whittaker, 2002) . In our study, we investigated the rate of B309 VLP internalization by evaluating the difference in fluorescence signal at the level of the cell membrane between drug-treated and non-treated cells by flow cytometry analysis. The optimal drug concentrations were in the range of those determined for FCV in CrFK cells (Stuart & Brown, 2006) . When total fluorescence intensity on drug-treated cells has been studied, in conditions compatible with the host cell metabolism, we found a significant difference with both chloroquine and cytochalasin D. The results obtained with chloroquine, known as an acidification inhibitor of the endosome, imply that B309 VLP entry could require a pH-dependent endocytic pathway. These results are in contrast with those that had previously shown MNV-1 entry to be pH independent (Gerondopoulos et al., 2010; Perry et al., 2009) . As internalization pathways can be cell typedependent (Miller & Hutt-Fletcher, 1992) , we could explain these contrasting results with reference to the different cell lines used in the two experiments. From this perspective, it might be interesting to evaluate the GIII.2 BoNoV internalization within bovine enterocyte as bovine kidney cells do not represent the main site of BoNoV infection. Another explanation could lie in the subtle differences in the internalization pathways between BoNoV and MuNoV. The results obtained for cytochalasin D are explained by the fact that the actin skeleton can be involved in several cellular processes, in particular the endocytosisassociated ones (Girao et al., 2008) . As even increasing concentrations of chlorpromazine did not affect the percentage of fluorescent cells, it can be concluded that, unlike in the case of FCV (Stuart & Brown, 2006) , B309 VLP do not use clathrin-coated pits to enter MDBK cells. By contrast, increased concentrations of nystatin (by 50 %) were shown to significantly increase both the percentage and fluorescence intensity of marked cells and these results imply that the cholesterol-dependent pathway could be involved in the internalization of B309 VLP. Nystatin is a sterol-binding drug that sequesters cholesterol, a prominent component of lipid rafts and it has already been demonstrated that some NoV (HuNoV and MuNoV) are capable of binding to glycosphingolipids Taube et al., 2009) . Increasing concentrations by 50 % of amiloride hydrochloride gave the same results. Macropinocytosis is considered to be a non-specific mechanism for internalization as it does not require a specific ligand-receptor interaction and where the macropinosome is just the cell response to extracellular stimulations. On the other hand, macropinocytosis is widely and constitutively used by antigen-presenting cells. As these cells could be the easiest entry portal for enteric viruses such as NoV, further studies on the relationship between macropinocytosis, dendritic cells and NoV might be interesting. Different studies on molecular prevalence and binding affinity seem to reveal that GIII.2 could not be at risk of transmission to human. However, the alternative use by viruses of different ligands or non-selective endocytic pathways could undermine these preliminary data. Moreover, in order to further analyse the zoonotic potential of BoNoV, studies on receptors and the binding pattern of the GIII.1 BoNoV would also have to be performed as some motifs in the GIII.1 capsid protein, including the RGD integrin-binding motif (Tan et al., 2003) , seem to be more related to the GI HuNoV motifs. The binding possibilities offered to viruses by the diverse carbohydrate structures on the cell surface can be great and the viral adaptation to this ligand range, e.g. by mutations or recombination, is a part of their evolution. Similar to HuNoV, different carbohydrate-binding patterns could be determined for both GIII.2 and GIII.1. Their respective specific receptors are as yet unknown, as are many other mechanisms of NoV cell invasion. Either the specific receptors or further steps could represent the real key points in BoNoV cell/host tropism and permissivity.
METHODS
Cell cultures. Spodoptera frugiperda insect cells (Sf9) were cultured at 28 uC with Sf900-II medium (Invitrogen). MDBK, BT, EBTr, GBK, EBL, Mac T, Bomac (kindly provided by Dr Donofrio, Parma University, Italy), and bovine bronchial cells were cultured at 37 uC with minimum essential medium (MEM) (Invitrogen) supplemented with 10 % heat inactivated FCS, 1 % of a non-essential amino acids preparation (NEAA) (Invitrogen) and 2 % of a penicillin-streptomycin combination (PS) (Invitrogen). Bovine jejunocytes (J8/13) (Loret et al., 2009) , kindly provided by Dr Rusu (University of Liège, Belgium), were cultured at 37 uC with Dulbecco's modified MEM (Invitrogen) supplemented with 20 % FCS, 1 % NEAA and 2 % PS (Invitrogen).
Reagents and antibodies. Neuraminidase from Clostridium perfringens (cleavage specificity a-2-3, a-2-6, a-2-8), a-galactosidase, a-chymotrypsin, trypsin, phospholipase C, phospho-N-glycanase F, NaIO 4 , heparinase II, chondroitinase ABC, chlorpromazine hydrochloride, nystatin, chloroquine diphosphate salt, amiloride hydrochloride hydrate, cytochalasin D and 7 actinomycin D were purchased from Sigma-Aldrich. Endocytosis inhibiting drugs were all diluted at 10 mM in RNase-free water (Invitrogen) (chlorpromazine hydrochloride and chloroquine diphosphate salt) or in DMSO (nystatin, amiloride hydrochloride hydrate and cytochalasin D). Alexa Fluor 488 goat anti-rabbit IgG mAb (GAR-488) was purchased from Invitrogen.
GIII.2 BoNoV and HV VLP. VLP of a GIII.2 genetically related BoNoV strain (B309), molecularly detected in a stool sample from a Belgian calf, were obtained as already mentioned elsewhere (Mauroy et al., 2009a) . Briefly, the sequence coding for the single capsid protein (GenBank accession no. EU794907, Bo/NoV/B309/2003/Be) was cloned into Bacmid (Bac-to-Bac system; Invitrogen), which was thereafter transfected into Sf9 cells. The recombinant baculovirus was used to infect Sf9 cells and the produced BoNoVLP were purified from supernatant by ultracentrifugation in sucrose gradient. The presence of capsid protein and viral particles was verified by both SDS-PAGE analysis and electron microscopy.
VLP of the HuNoV HV were obtained in the same way from a plasmid containing the HV ORF2 (kindly provided by Dr Vinjé, Centers for Disease Control, USA). The presence of capsid protein and viral particles was verified by both SDS-PAGE analysis and electron microscopy.
Antigens from an Sf9 cell culture infected by a wild-type baculovirus (AcMNPV) were also produced and submitted to a similar procedure of purification. Protein concentration was measured by BCA (Pierce) and on a NanoDrop1000 spectrophotometer (Thermo Scientific).
Rabbit polyclonal serum against B309 VLP. Three New Zealand rabbits were injected subcutaneously with 25 mg of antigen (B309 VLP, HV VLP or PBS). Antigens were diluted in PBS with complete Freund's adjuvant. Two additional immunizations were carried out at intervals of 21 days with the same amount of antigens diluted in PBS with incomplete Freund's adjuvant. Rabbits were euthanized by exsanguination 21 days after the last immunization. Sera (called rabbit-aB309, rabbit-aHV and rabbit-negative) were heat inactivated (30 min at 56 uC) and tested for reactivity and specificity in an ELISA format. All experimental procedures were approved by the Institutional Animal Care and Use Committee at the University of Liège (reference of the protocol: 581).
Indirect immunofluorescence staining on cell culture-binding assay. Confluent monolayers of MDBK, EBTr, Bomac, BT, EBL, MacT, bronchial cells and bovine jejunocytes were subcultured on coverslips in 24-well plates (Greiner) the day before their use in the experiment. Following this, the medium was removed and cells were incubated for 30 min in PBS supplemented with heat inactivated horse serum at 10 % (v/v) (PBS-HS). Some coverslips were pretreated after a wash with PBS with 200 ml per well of a dilution of NaIO 4 (5 mM) for 45 min at 37 uC. NaIO 4 was then removed and coverslips were washed once with PBS and then incubated at 37 uC for 15 min with a 1 % (w/v) solution of glycine. Coverslips were placed on ice and incubated with 200 ml antigen solution in PBS at 1 ng ml 21 (B309 VLP, HV VLP or wild-type AcMNPV) for 1 h at 4 uC on a rocking platform. Antigens were removed and cells were then washed three times with PBS-HS and fixed for 45 min at 4 uC with a 2 % solution of paraformaldehyde in PBS. Cells were washed three times with PBS and then blocked with PBS-HS for 1 h at 37 uC. After three washes with PBS, cells were incubated with the 10 000-fold PBS diluted rabbit anti-B309 VLP serum for 1 h at 37 uC. Coverslips were washed three times with PBS-HS and then incubated for 1 h at 37 uC with an Alexa Fluor 488 conjugated, 1000-fold PBS diluted, goat antirabbit IgG. Cells were washed three times with PBS-HS and coverslips were mounted with ProLong gold anti-fade reagent (Invitrogen) before epifluorescent microscopy analysis, performed with a Nikon Eclipse TC2000 microscope equipped with an X-Cite120 Fluorescence Illumination System and a DC300F camera (Leica). The same assay was also performed on MDBK cells after treatment with cytochalasin D (2 mM) or chloroquine (600 mM) for 1 or 3 h.
Flow cytometry analysis on cell-binding assay. MDBK cells were selected for flow cytometry analysis (FACS). Cells were grown to confluence and then seeded into 96-well plates (150 000 cells per well) and incubated for 1 h at 37 uC. Cells were pelleted at 250 g and then washed once with PBS-HS. Cells were then pelleted and incubated at 37 uC for 1 h (or overnight for heparinase and chondroitinase treatment) with 100 ml of different reagent solutions: NaIO 4 at 50 and 5 mM; phospho-N-glycanase F, galactosidase, neuraminidase and phospholipase C at 5 and 1 U ml 21 ; heparinase and chondroitinase at 10 U ml 21 ; trypsin, and chymotrypsin at 10 and 1 mg ml
21
. After 45 min of incubation, NaIO 4 solutions were removed, replaced with the same amount of 1 % glycine (w/v) and incubated for 15 min at 37 uC. All cells were pelleted, washed once with ice-cold PBS-HS, pelleted and then incubated on ice with 100 ml of antigen (B309 VLP, HV VLP or PBS) at 0.5 ng ml 21 dilution in PBS-HS complemented with 1 % azide (w/v) (PBS-HS-a). After incubation, cells were pelleted, washed twice for 5 min with PBS-HS-a and then incubated on ice for 45 min with a 5000-fold diluted rabbit-aB309 in PBS-HS-a. Following this, cells were pelleted, washed twice for 5 min with PBS-HS-a and then incubated on ice for 30 min with a 10 000-fold diluted GAR-488 in PBS-HS-a. After incubation, cells were pelleted, washed three times for 5 min with PBS-HS-a, diluted in non-complemented ice-cold MEM and maintained on ice. Flow cytometry acquisitions and analyses were performed on a three-laser Becton Dickinson fluorescence-activated cell sorter (FACSAria).
Flow cytometry analysis on cell internalization assay. The day before the internalization experiment, MDBK cells were seeded into 96-well plates (150 000 cells per well). Cells were incubated with 100 ml antigen (B309 VLP, HV VLP or PBS) at 0.5 ng ml 21 dilution in PBS-HS at 4 uC for 1 h. Unbound antigens were removed and cells were incubated in MEM at 4 , 21 or 37 uC for 1 h. After incubation, cells were pelleted, washed twice for 5 min with ice-cold PBS-HS-a and then incubated on ice for 45 min with a 5000-fold diluted rabbitaB309 in PBS-HS-a. Following this, cells were pelleted, washed twice for 5 min with ice-cold PBS-HS-a and then incubated on ice for 30 min with a 10 000-fold diluted GAR-488 in PBS-HS-a. After incubation, cells were pelleted, washed three times for 5 min with PBS-HS, diluted in non-complemented ice-cold MEM and maintained on ice. Flow cytometry acquisitions and analyses were performed on a three-laser Becton Dickinson fluorescence-activated cell sorter (FACSAria). The same assay was then performed on Bomac cells at 4 and 37 uC. All conditions were analysed in triplicate.
The same assay was also performed after drug treatment of cells. A preliminary experiment was performed on MDBK cells in 96-well plates at 80 % confluence in order to define concentrations of the used drugs (cytochalasin, chloroquine, chlorpromazine, nystatin and amiloride hydrochloride) compatible with cell metabolism. Briefly, cells were grown overnight with different concentrations of drugs [the range was primarily defined following the study of Stuart & Brown (2006) on the FCV]. Cell viability (above or equal to 95 %) and metabolism were assessed by trypan blue and MTT tests to determine optimal drug concentration. The day before the internalization experiment, MDBK cells, grown at confluence, were seeded into 25 cm 2 culture flasks with complete MEM, with or without drugs diluted at the above defined concentrations. The following tests were performed as already described above. All conditions were analysed in triplicate. The same experiment was finally performed in triplicate with MDBK cells previously treated with a 50 % increased concentration of both nystatin and amiloride hydrochloride.
Confocal microscopy. Confluent monolayer of MDBK was subcultured on coverslips in 24-well plates (Greiner) the day before their use in the experiment. Following this, the medium was removed and cells were incubated for 30 min in PBS-HS. Coverslips were washed once with PBS and then incubated at 4 uC for 1 h. Unbound antigens were removed and cells were incubated in MEM at 37 uC for 1 h or fixed directly. MEM was then removed and cells were washed three times with PBS-HS. Cells were fixed for 45 min at 4 uC with a 2 % solution of paraformaldehyde in PBS and then permeabilized with PBS-NP-40 0.1 % for 15 min. Cells were washed three times with PBS-HS and then incubated with the 5000-fold PBS diluted rabbit anti-B309 VLP serum for 1 h at 37 uC. Coverslips were washed three times with PBS-HS and then incubated for 1 h at 37 uC with an Alexa Fluor 488 conjugated, 1000-fold PBS diluted, goat anti-rabbit IgG. Coverslips were washed three times with PBS-HS and then incubated for 1 h at 37 uC with an Alexa Fluor 488 conjugated, 1000-fold dilution of 7 actinomycin D. Coverslips were washed three times with PBS-HS and then mounted with ProLong gold anti-fade reagent (Invitrogen) before confocal microscopy analyses, performed with a TCS SP confocal microscope (Leica).
Statistical analysis. Significance of the differences between means (three replicates of a single experiment) was assessed with the Wilcoxon-Mann-Whitney rank sum test (P,0.05).
